Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
[
Title
]
Type
Year
Filters:
Author
is
Jorgensen, Jeffrey
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
C
Jabbour E
,
Sasaki K
,
Ravandi F
,
Huang X
,
Short NJ
,
Khouri M
,
Kebriaei P
,
Burger J
,
Khoury J
,
Jorgensen J
, et al.
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Cancer. 2018.
PubMed
Google Scholar
Ravandi F
,
Kreitman RJ
,
Tiacci E
,
Andritsos L
,
Banerji V
,
Barrientos JC
,
Bhat SA
,
Blachly JS
,
Broccoli A
,
Call T
, et al.
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.
Blood Cancer J. 2022;12(12):165.
PubMed
Google Scholar
E
Jain N
,
Lamb AE
,
O'Brien S
,
Ravandi F
,
Konopleva M
,
Jabbour E
,
Zuo Z
,
Jorgensen J
,
Lin P
,
Pierce S
, et al.
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.
Blood. 2016.
PubMed
Google Scholar
H
Jabbour E
,
Richard-Carpentier G
,
Sasaki Y
,
Konopleva M
,
Patel K
,
Roberts K
,
Gu Z
,
Wang F
,
Huang X
,
Sasaki K
, et al.
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.
Lancet Haematol. 2020;7(7):e523-e533.
PubMed
Google Scholar
R
Kantarjian H
,
Thomas D
,
Jorgensen J
,
Kebriaei P
,
Jabbour E
,
Rytting M
,
York S
,
Ravandi F
,
Garris R
,
Kwari M
, et al.
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.
Cancer. 2013.
PubMed
Google Scholar
Kantarjian H
,
Haddad FG
,
Jain N
,
Sasaki K
,
Short NJ
,
Loghavi S
,
Kanagal-Shamanna R
,
Jorgensen J
,
Khouri I
,
Kebriaei P
, et al.
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia.
J Hematol Oncol. 2023;16(1):44.
PubMed
Google Scholar